Skip to content
777 Sourcing.

Capability

therapeutics development

Suppliers
4
States & provinces
3
Countries
1

4 therapeutics development suppliers across 3 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

APTAVIAN INC.

JACOBUS, PA

AptAvian, Inc. is a biotechnology company formed in 2023 by two firms in aptamer production and airborne detection engineering to commercialize aptagenic technology platforms. It uses aptamers—single-strand DNA and RNA molecules with selective binding properties—to develop detection and therapeutic capabilities against airborne pathogens and biological threats. Over $3 million of R&D investment has produced multiple patents.

airborne pathogen detectionaptamer technologybioradar monitoringIVS (In Vivo Simulatum) testinglateral flow assay development

ASTRIA BIOSCIENCES, INC.

PITTSBURGH, PA

Astria Biosciences, Inc is a Pittsburgh-based startup company developing diagnostic and therapeutic solutions for cerebrovascular disease. It is developing a blood-based diagnostic test to detect and risk-stratify cerebral aneurysms as well as molecular-based therapies to combat this disease. Its work is supported by NSF SBIR Phase I # 2335396.

diagnosticshigh-throughput analysismolecular biology

BIOINCEPT

MASON, OH

BioIncept, a wholly owned subsidiary of Prince Biotech, is a clinical-stage biotechnology company developing breakthrough therapeutics and diagnostics built on its proprietary discovery of the PreImplantation Factor (PIF). The company is advancing novel therapies in regenerative medicine, immune modulation, and reproductive health, focused on improving IVF outcomes and tackling conditions such as autoimmunity and neuro-regeneration.

diagnostics developmentimmune modulationregenerative medicinereproductive health

GLYCOMANTRA INC

HALETHORPE, MD

GlycoMantra is a biologics company and start-up biotechnology firm developing novel therapeutics for unmet medical needs in metastatic castration-resistant prostate cancer, NASH liver fibrosis, and type 2 diabetes. It leads translational glycobiology research and develops carbohydrate-based therapeutics for cancer, fibrosis, and diabetes, including high-affinity galectin-3 antagonists (GM100 series), a CAR-T asset for kidney cancer, and a small molecule drug for metastatic colorectal cancer.

protein or antibody purificationtranslational glycobiology research

Related capabilities

Other processes offered by the shops that list therapeutics development.

Browse all capabilities